<DOC>
	<DOCNO>NCT02193958</DOCNO>
	<brief_summary>A Phase 1/2a Dose Escalation Study FF-10501-01 Patients Relapsed Refractory Hematological Malignancies determine safety tolerability . A total 6 cohort enrol Phase 1 establish MTD . Phase 2 consist 2 cohort : Cohort 1 include subject high-risk MDS/CMML relapse refractory prior therapy ; Cohort 2 include subject AML relapse refractory prior therapy ≥ 60 hears age candidate therapy .</brief_summary>
	<brief_title>Study FF-10501-01 Patients With Relapsed Refractory Hematological Malignancies</brief_title>
	<detailed_description>Subjects receive FF-10501-01 orally twice daily schedule 14 day repeat every 28 day ( =1 cycle ) . Disease assessment , include analysis blood bone marrow aspirate , perform end Cycle 1 every 2 cycle thereafter . Subjects demonstrate objective response stable disease allow continue therapy FF-10501-01 progression disease , observation unacceptable adverse event , intercurrent illness change condition prevent study participation .</detailed_description>
	<criteria>Confirmed advance hematologic malignancy ; Highrisk MDS/CMML ( define ≥ 10 % peripheral blood marrow blast and/or IPSS score ≥ 1.5 ) relapse refractory prior therapy AML relapse refractory prior therapy , ≥ 60 year age candidate therapy At least 3 week beyond last chemotherapy , target anticancer agent , major surgery experimental treatment recover acute toxicity ( ≤ Grade 1 ) . Hydroxyurea use control peripheral blast count permit Day 7 treatment study . Adequate performance status : ECOG ≤ 2 ; Adequate renal hepatic function : creatinine ≤ 2.0 mg/dL , calculate creatinine clearance ≥ 45 mL/min total bilirubin ≤ 2 time upper limit normal ( ULN ) ALT/AST ≤ 2 time ULN Negative serum pregnancy test Ability provide write informed consent Known history coronary artery disease , angina , myocardial infarction , congestive heart failure , cardiac arrhythmia type heart disease present within last 6 month Known family history hereditary heart disease QT interval correct rate ( QTc ) &gt; 450 msec electrocardiogram ( ECG ) obtain Screening Concomitant medication ( ) may cause QTc prolongation induce Torsades de Pointes , exception antimicrobial use standard care prevent treat infection drug consider Investigator essential care patient . Presence active central nervous system ( CNS ) leukemia . Subjects adequately treat CNS leukemia document 2 consecutive cerebrospinal fluid sample negative leukemia cell eligible . Subjects history CNS leukemia require undergo cerebrospinal fluid sample eligibility . Known positive HIV , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) . Active infection require IV antiinfective usage within last 7 day prior study treatment . Any medical intervention condition could compromise adherence study requirement confound interpretation study result . Pregnant breastfeeding . Treatment investigational product within 28 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>